Inhibitor Therapeutics, Inc. filed its 10-K on Mar 30, 2022 for the period ending Dec 31, 2021. In this report its auditor, Cherry, Bekaert & Holland, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.132 USD | +48.36% | +9.45% | +43.48% |
29/03 | Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board | CI |
1st Jan change | Capi. | |
---|---|---|
+43.48% | 1.53Cr | |
+7.11% | 11TCr | |
+11.05% | 11TCr | |
+0.64% | 2.23TCr | |
-12.21% | 2.22TCr | |
-5.38% | 1.94TCr | |
-37.85% | 1.79TCr | |
-6.03% | 1.72TCr | |
+7.88% | 1.43TCr | |
+34.52% | 1.25TCr |
- Stock Market
- Equities
- INTI Stock
- News Inhibitor Therapeutics, Inc.
- Inhibitor Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt